Mesa Laboratories, Inc. (NASDAQ:MLAB) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC decreased its position in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) by 10.9% in the fourth quarter, HoldingsChannel reports. The firm owned 2,073 shares of the medical instruments supplier’s stock after selling 254 shares during the quarter. SG Americas Securities LLC’s holdings in Mesa Laboratories were worth $273,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Mesa Laboratories by 20.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,103 shares of the medical instruments supplier’s stock valued at $1,312,000 after acquiring an additional 1,708 shares during the period. Barclays PLC lifted its position in Mesa Laboratories by 357.4% during the third quarter. Barclays PLC now owns 8,837 shares of the medical instruments supplier’s stock valued at $1,148,000 after purchasing an additional 6,905 shares during the period. Geode Capital Management LLC boosted its holdings in Mesa Laboratories by 4.8% in the third quarter. Geode Capital Management LLC now owns 124,761 shares of the medical instruments supplier’s stock valued at $16,205,000 after purchasing an additional 5,771 shares during the last quarter. Victory Capital Management Inc. grew its position in Mesa Laboratories by 90.3% during the 3rd quarter. Victory Capital Management Inc. now owns 14,001 shares of the medical instruments supplier’s stock worth $1,818,000 after purchasing an additional 6,643 shares during the period. Finally, Franklin Resources Inc. grew its position in Mesa Laboratories by 27.8% during the 3rd quarter. Franklin Resources Inc. now owns 6,444 shares of the medical instruments supplier’s stock worth $828,000 after purchasing an additional 1,403 shares during the period. Hedge funds and other institutional investors own 90.60% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com downgraded Mesa Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, November 13th.

Mesa Laboratories Stock Performance

MLAB opened at $138.90 on Thursday. The stock has a market cap of $754.23 million, a P/E ratio of -3.05 and a beta of 0.83. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.70 and a quick ratio of 0.51. The firm has a fifty day moving average price of $133.67 and a 200 day moving average price of $125.66. Mesa Laboratories, Inc. has a 1 year low of $83.68 and a 1 year high of $152.75.

Mesa Laboratories (NASDAQ:MLAB) last posted its earnings results on Tuesday, February 4th. The medical instruments supplier reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.41 by $0.66. Mesa Laboratories had a negative net margin of 107.56% and a positive return on equity of 28.52%. Equities research analysts anticipate that Mesa Laboratories, Inc. will post 7.39 earnings per share for the current year.

Mesa Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 17th. Stockholders of record on Friday, February 28th will be given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.46%. The ex-dividend date is Friday, February 28th. Mesa Laboratories’s dividend payout ratio (DPR) is presently -1.40%.

About Mesa Laboratories

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.